Prior to initiation of DESCOVY, patients should be tested for hepatitis B virus infection [see WARNINGS AND PRECAUTIONS].
Estimated creatinine clearance, urine glucose, and urine protein should be assessed before initiating DESCOVY therapy and should be monitored during therapy in all patients [see WARNINGS AND PRECAUTIONS].
DESCOVY is a two-drug fixed dose combination product containing 200 mg of emtricitabine (FTC) and 25 mg of tenofovir alafenamide (TAF). The recommended dosage of DESCOVY is one tablet taken orally once daily with or without food in adults and pediatric patients 12 years of age and older with body weight at least 35 kg and creatinine clearance greater than or equal to 30 mL per minute [see Use In Specific Populations and CLINICAL PHARMACOLOGY].
For specific dosing recommendations for coadministered third agents, refer to their respective prescribing information [see DRUG INTERACTIONS].
DESCOVY is not recommended in patients with estimated creatinine clearance below 30 mL per minute [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].
